Luciana Borio, M.D., is a Venture Partner at ARCH Venture Partners. In this capacity, she advises on and helps develop new investment opportunities related to biologics manufacturing, clinical trials, novel therapies and areas with large unmet clinical needs.
Dr. Borio is a specialist in biodefense, emerging infectious diseases, medical product development, and complex public health emergencies. Prior to joining ARCH, she was a senior vice president at In-Q-Tel, an independent, non-profit, strategic investment firm that works to deliver innovative technology solutions to support the missions of the U.S. Intelligence Community. Past positions include serving as a member of President Biden’s transition COVID-19 Advisory Board and Director for Medical and Biodefense Preparedness at the National Security Council (2017-2019), where she coordinated the response to the Ebola epidemic in West Africa, efforts to combat antimicrobial resistance, and the development of an Executive Order to modernize America’s influenza vaccines. Prior to that, she was the Acting Chief Scientist of the U.S. Food and Drug Administration (2015-2017) and the Assistant Commissioner for Counterterrorism Policy of the FDA (2010-2017).
Dr. Borio is an adjunct Assistant Professor of Medicine at Johns Hopkins University (2003-present), where she continues to practice medicine part-time. She is also a senior fellow for global health at the Council on Foreign Relations.
Dr. Borio obtained her M.D. from George Washington University, completed a residency in internal medicine at New York-Presbyterian/Weill Cornell Medical Center, and a combined fellowship in infectious diseases at Johns Hopkins and critical care at the National Institutes of Health.